MorphoSys AG (ETR:MOR – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as €68.00 ($72.34) and last traded at €67.70 ($72.02), with a volume of 122121 shares traded. The stock had previously closed at €67.70 ($72.02).
MorphoSys Stock Performance
The company has a current ratio of 3.08, a quick ratio of 3.49 and a debt-to-equity ratio of 526.17. The firm has a market capitalization of $2.55 billion, a P/E ratio of -12.24, a P/E/G ratio of 0.06 and a beta of 0.61. The firm has a 50-day moving average of €66.19 and a two-hundred day moving average of €43.03.
About MorphoSys
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
Further Reading
- Five stocks we like better than MorphoSys
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Comprehensive Analysis of PayPal Stock
- Following Congress Stock Trades
- Intuitive Surgical Stock Can Trend Much Higher This Year
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.